**Company:** Bausch & Lomb Inc.
**Country:** United States (Tampa, Florida facility)
**Audit Dates:** March 12–20, 2026
**Warning Letter Issued:** September 4, 2026
In March 2026, FDA inspected a U.S. manufacturer of sterile prescription and over-the-counter (OTC) drug products produced by aseptic processing. Investigators identified significant deficiencies in environmental and personnel monitoring, Restricted Access Barrier System (RABS) design, aseptic working practices, airflow management, and media fills (aseptic process simulations). The firm’s response to the Form FDA 483 was judged inadequate, leading to the issuance of a Warning Letter. Products manufactured under these conditions were considered adulterated under section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act.
### Key Observations
**Environmental and Personnel Monitoring**
Monitoring in classified areas was inadequate. Important contamination sources (such as telephones in the aseptic area) were not sufficiently sampled. Some culture media were unsuitable or damaged. Between 2023 and 2025, out-of-limit recoveries of Gram-negative rods including *Serratia marcescens* and *Stenotrophomonas maltophilia*—organisms typically linked to moisture—were repeatedly found in ISO 5 areas. Production continued without effective CAPA. Microbiological deviations and adverse trends in the Water for Injection system and monitoring programs were not adequately investigated, and recovered organisms were not sufficiently identified. Of particular concern, *Pseudomonas aeruginosa* and *Aspergillus brasiliensis* recovered from the operating environment matched organisms found in consumer complaint samples.
**RABS Design and Airflow**
The RABS line exhibited design shortcomings, including ergonomic problems during component transfer, insufficient barrier protection, and incomplete demonstration of unidirectional airflow (especially during setup and interventions). Dynamic smoke studies did not fully confirm protection across critical operations.
**Aseptic Technique and Cleanroom Behavior**
Operators repeatedly demonstrated poor practices during filling: reaching over exposed sterilized containers to clear jams, failing to disinfect components before and between uses, blocking unidirectional airflow, contacting sterile surfaces of tools and then returning the containers to the line, exposing transfer bags to ISO 7 environments, and using non-dedicated tools for waste removal.
**Media Fills / Aseptic Process Simulations**
Media fills used substantially fewer units than commercial batch sizes and therefore did not adequately represent contamination risks. A July 2025 media fill on one line failed with contamination by the fungus *Neovaginatispora magiferae* and the spore-forming Gram-positive bacterium *Geodermatophilus obscurus*.
These findings align with requirements in 21 CFR 211.42(c)(10) (adequate space and controls to prevent contamination or mix-ups in aseptic areas), 21 CFR 211.113(b) (procedures to prevent microbiological contamination of sterile products, including validation of aseptic processes), and the principles set out in FDA’s guidance *Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice*.
### Why It Matters
Sterility assurance for aseptically processed products rests on facility design, barrier systems, airflow, disciplined personnel behavior, robust environmental monitoring, and process simulations that truly challenge the worst-case conditions. When any of these elements is weak, the risk of microbial contamination rises sharply. A finished-product sterility test alone cannot compensate for upstream control failures. Persistent recoveries of water-associated organisms, identical isolates in complaints, and media-fill failures signal systemic issues that can affect patient safety and trigger product recalls, import alerts, or further enforcement. Quality units must have the authority and data to stop production when trends indicate loss of control.
### Implementations
- Rebuild the environmental and personnel monitoring program with scientifically justified sampling locations (including high-risk points such as telephones and intervention zones), frequencies, action/alert limits, growth-media suitability checks, and real-time trending. Require full identification of isolates and thorough investigation of all out-of-limit results and adverse trends.
- Commission an independent assessment of RABS and cleanroom design. Address ergonomics, barrier integrity, and unidirectional airflow. Conduct dynamic smoke studies (using neutrally buoyant media) under actual operating conditions, including routine and non-routine interventions, after design remediation.
- Strengthen aseptic technique training and oversight. Qualify all personnel who enter ISO 5 areas through media fills. Implement behavioral observations, video review where appropriate, and immediate correction of practices that compromise airflow or sterile surfaces. Update SOPs and retrain before resuming critical operations.
- Redesign media-fill (aseptic process simulation) protocols so that unit numbers, duration, interventions, personnel, and line speed represent the worst-case commercial process. Investigate and fully close all historical media-fill failures; re-qualify lines only after root-cause remediation.
- Perform a comprehensive contamination-hazard risk assessment covering human interventions, material and personnel flows, equipment suitability, and facility layout. Implement the resulting CAPA with clear timelines and verification of effectiveness.
- Evaluate retain samples of distributed batches for microbiological quality (including objectionable organisms) and other critical attributes. Assess the need for customer notification or recall based on the risk evaluation.
- Ensure the Quality Unit has documented authority, resources, and procedures to review all monitoring data, approve process changes, and halt manufacturing when control is lost. Establish clear quality agreements if contract manufacturing is involved.
### Practical Next Steps
1. Map every observation to the specific CFR citations and FDA aseptic-processing guidance requirements.
2. Engage an independent expert to lead the design and monitoring assessments.
3. Develop a time-bound remediation plan with measurable success criteria and management review gates.
4. Re-qualify all affected processes and personnel only after CAPA effectiveness is demonstrated.
5. Update internal audit checklists and inspection-readiness materials to include these control points.
Addressing these gaps proactively protects product quality, patient safety, and regulatory standing. Facilities that treat environmental monitoring, barrier design, and media fills as living control systems rather than check-box exercises are far better positioned when investigators arrive.
**Related Keywords:** FDA Warning Letter, aseptic processing, RABS deficiencies, media fill failure, environmental monitoring, personnel monitoring, unidirectional airflow, sterile OTC manufacturing, 21 CFR 211.113, aseptic process simulation, contamination control strategy, Quality Unit oversight
**Hashtags:** #FDAWarningLetter #AsepticProcessing #CGMP #MediaFill #RABS #SterileManufacturing #ContaminationControl #PharmaQuality #InspectionReadiness #QualityCulture
---
**Second Recent Case: Analytical Testing and Oversight Gaps at a Taiwanese OTC Manufacturer**
**Company:** TCI Co., Ltd BioCosme PABP BRANCH
**Country:** Taiwan (Pingtung County facility)
**Audit Dates:** March 9–13, 2026
**Warning Letter Issued:** September 2, 2026
FDA identified failures to perform required finished-product assay testing before release, inadequate identity and conformity testing of incoming components (with over-reliance on supplier certificates of analysis), incomplete process validation that did not match actual batch records, and insufficient qualification/monitoring of a pharmaceutical water system (missing TOC, conductivity, and microbial limits). Quality Unit oversight of changes and investigations was also deficient. The firm’s 483 response lacked supporting evidence of effective corrections. These issues violate 21 CFR 211.165(a), 211.84(d), and 211.100(a).
### Why It Matters
Releasing products without confirming identity, strength, and purity, or using unqualified components and water, removes the scientific basis for batch disposition. Incomplete validation means processes may not consistently deliver the quality claimed on the label.
### Implementations
Establish robust quality agreements defining testing and release responsibilities, perform all required USP identity and impurity tests (or fully qualify supplier methods with periodic verification), align process-validation documentation with actual manufacturing steps, and fully qualify water systems with chemical and microbiological specifications and trending.
**Related Keywords (additional):** component testing, supplier qualification, process validation, pharmaceutical water, Quality Unit, OTC drugs, Taiwan manufacturer, 21 CFR 211.165, certificate of analysis reliance
**Hashtags (additional):** #ComponentTesting #ProcessValidation #SupplierQualification #PharmaWater #OTCManufacturing
These cases underscore that foundational CGMP controls—monitoring, design, testing, validation, and oversight—remain the most frequent and consequential inspection findings. Organizations that translate regulatory expectations into practical, verified systems will reduce risk and improve readiness.
Post a Comment